Anika Therapeutics Inc
$ 15.37
-0.32%
24 Apr - close price
- Market Cap 221,654,000 USD
- Current Price $ 15.37
- High / Low $ 15.62 / 15.01
- Stock P/E N/A
- Book Value 10.33
- EPS -0.70
- Next Earning Report 2026-04-29
- Dividend Per Share N/A
- Dividend Yield 0 %
- Next Dividend Date -
- ROA -0.04 %
- ROE -0.07 %
- 52 Week High 16.24
- 52 Week Low 7.87
About
Anika Therapeutics, Inc., is a joint preservation company in the United States, Europe, and internationally. The company is headquartered in Bedford, Massachusetts.
Analyst Target Price
$17.50
Quarterly Earnings
| Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 | Mar 2024 | Dec 2023 | Sep 2023 | Jun 2023 | Mar 2023 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Reported Date | 2026-03-10 | 2025-10-29 | 2025-07-30 | 2025-05-06 | 2025-03-11 | 2024-10-31 | 2024-08-08 | 2024-05-08 | 2024-03-13 | 2023-11-02 | 2023-08-08 | 2023-05-09 |
| Reported EPS | 0.31 | 0.04 | -0.33 | -0.06 | -0.03 | -0.25 | -0.01 | -0.31 | -4.3 | -0.45 | -0.19 | -0.47 |
| Estimated EPS | -0.135 | -0.11 | -0.08 | 0.09 | 0.09 | -0.01 | 0.05 | -0.19 | -0.26 | -0.37 | -0.27 | -0.3 |
| Surprise | 0.445 | 0.15 | -0.25 | -0.15 | -0.12 | -0.24 | -0.06 | -0.12 | -4.04 | -0.08 | 0.08 | -0.17 |
| Surprise Percentage | 329.6296% | 136.3636% | -312.5% | -166.6667% | -133.3333% | -2400% | -120% | -63.1579% | -1553.8462% | -21.6216% | 29.6296% | -56.6667% |
Next Quarterly Earnings
| Mar 2026 | |
|---|---|
| Reported Date | 2026-04-29 |
| Fiscal Date Ending | 2026-03-31 |
| Estimated EPS | -0.21 |
| Currency | USD |
Next Dividend Records
| Dividend per share (year): | - |
| Dividend Yield | - |
| Next Dividend Date | - |
| Ex-Dividend Date | - |
Recent News: ANIK
2026-04-23 20:39:35
Anika Therapeutics unveiled its new Integrity Implant System at the Shoulder360 conference, inviting attendees to experience the technology firsthand. This launch reinforces the company's commitment to innovation in orthopedic solutions and follows a successful case report demonstrating superior outcomes for its Integrity system in rotator cuff repair. Anika is also expanding its market reach through a distribution partnership with J&J Medtech for its osteoarthritis therapies in the U.S.
2026-04-23 04:09:16
Anika Therapeutics (ANIK) is projected to announce its Q1 2026 earnings before market open on Wednesday, April 29th, with analysts expecting an EPS of ($0.07) and revenue of $28.142 million. The company reported a beat in its last quarter but faces negative return on equity and net margin, with forecasts of negative EPS for the current fiscal year. ANIK has a "Hold" consensus rating with an average price target of $17.00.
2026-04-19 12:12:00
The article analyzes Anika Therapeutics Inc. (NASDAQ: ANIK), noting a current breakout and positive sentiment that could lead to higher levels if sustained. It highlights elevated downside risk due to the lack of additional long-term support signals and provides three AI-generated trading strategies tailored to different risk profiles.
2026-04-18 07:10:28
Anika Therapeutics (NASDAQ:ANIK) saw its share price cross above its 200-day moving average, reaching $16.00 with a volume of 73,404 shares. Analyst opinions are mixed, with some upgrading to "outperform" or "strong-buy" and others maintaining a "sell" rating, leading to a consensus "Hold" with a $17.00 price target. Despite beating quarterly earnings and revenue estimates, the company remains unprofitable and analysts project a negative EPS for the current year.
2026-04-16 19:40:11
This article provides the edited transcript of Anika Therapeutics Inc.'s Q3 2025 earnings call, which took place on November 5, 2025, at 01:30 PM GMT. It includes a summary of key positive and negative points from the earnings report, highlighting strong commercial channel revenue growth, progress in regulatory filings, and significant operating cash flow, alongside challenges such as total revenue decline due to OEM pricing pressure and reduced gross margin. The transcript features introductory remarks from the unnamed moderator and Matt Hall, Director of Corporate Development and Investor Relations.
2026-04-16 08:40:11
Anika Therapeutics, Inc. (NASDAQ: ANIK) announced it will release its first quarter 2026 financial results before the market opens on Wednesday, April 29, 2026. This will be followed by a conference call at 8:30 a.m. ET to discuss the results and business highlights. Investors can access the call via phone or a live audio webcast on Anika's website.
